Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators.

Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.

PMID:
30982686
2.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen KJ, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch SD.

Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15.

PMID:
30770959
3.

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuendgen A, Ringhoffer M, Hertenstein B, Martens UM, Grießhammer M, Bernhard H, Krauter J, Girschikofsky M, Wolf D, Lange E, Westermann J, Koller E, Kremers S, Wattad M, Heuser M, Thol F, Göhring G, Haase D, Teleanu V, Gaidzik V, Benner A, Döhner K, Ganser A, Paschka P, Döhner H.

Leukemia. 2019 Aug;33(8):1923-1933. doi: 10.1038/s41375-019-0395-y. Epub 2019 Feb 6.

4.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.

PMID:
30610279
5.

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators.

J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11.

PMID:
29750632
6.

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.

Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke C, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf HH, Sezer O, Bargou R, Jung W, Trümper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schäfer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H.

Haematologica. 2016 Nov;101(11):1398-1406. Epub 2016 Aug 4.

7.

Best practices for perinatal palliative care.

Ryan A, Bernhard H, Fahlberg B.

Nursing. 2015 Oct;45(10):14-5. doi: 10.1097/01.NURSE.0000471422.49754.9b. No abstract available.

PMID:
26372234
8.

Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.

Sylvie L, Silvia S, Salah-Eddin AB, Markus F, Florian L, Peter TP, Bernhard H, Martin A, Alexander N.

Eur J Cancer. 2015 Sep;51(14):1918-26. doi: 10.1016/j.ejca.2015.07.002. Epub 2015 Jul 24.

PMID:
26216588
9.

A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes.

Khandelwal N, Breinig M, Speck T, Michels T, Kreutzer C, Sorrentino A, Sharma AK, Umansky L, Conrad H, Poschke I, Offringa R, König R, Bernhard H, Machlenkin A, Boutros M, Beckhove P.

EMBO Mol Med. 2015 Apr;7(4):450-63. doi: 10.15252/emmm.201404414.

10.

In reply.

Bernhard HF, Holz FG.

Dtsch Arztebl Int. 2014 May 16;111(20):366. doi: 10.3238/arztebl.2014.0366b. No abstract available.

11.

Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates.

Karbach J, Gnjatic S, Biskamp M, Atmaca A, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jäger E.

Cancer Immunol Res. 2014 May;2(5):404-9. doi: 10.1158/2326-6066.CIR-13-0200. Epub 2014 Feb 5.

12.

Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.

Smith SN, Sommermeyer D, Piepenbrink KH, Blevins SJ, Bernhard H, Uckert W, Baker BM, Kranz DM.

J Mol Biol. 2013 Nov 15;425(22):4496-507. doi: 10.1016/j.jmb.2013.08.007. Epub 2013 Aug 14.

13.

HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.

Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, Nittel S, Bernhard H, Domschke C, Schuetz F, Sohn C, Beckhove P.

Oncoimmunology. 2013 Jun 1;2(6):e24962. Epub 2013 May 15.

14.

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.

Witzens-Harig M, Hose D, Jünger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Rème T, Gueckel B, Meißner T, Hundemer M, Ho AD, Rossi JF, Neben K, Bernhard H, Goldschmidt H, Klein B, Beckhove P.

Blood. 2013 May 30;121(22):4493-503. doi: 10.1182/blood-2012-05-429415. Epub 2013 Apr 19.

PMID:
23603913
15.

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.

Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueck P, Caca K, Prasnikar N, Kullmann F, Günther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jäger E.

Br J Cancer. 2013 Feb 5;108(2):265-70. doi: 10.1038/bjc.2012.555. Epub 2013 Jan 17.

16.

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

Sommermeyer D, Conrad H, Krönig H, Gelfort H, Bernhard H, Uckert W.

Int J Cancer. 2013 Mar 15;132(6):1360-7. doi: 10.1002/ijc.27792. Epub 2012 Sep 14.

17.

The efficiency of human cytomegalovirus pp65(495-503) CD8+ T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidases.

Urban S, Textoris-Taube K, Reimann B, Janek K, Dannenberg T, Ebstein F, Seifert C, Zhao F, Kessler JH, Halenius A, Henklein P, Paschke J, Cadel S, Bernhard H, Ossendorp F, Foulon T, Schadendorf D, Paschen A, Seifert U.

J Immunol. 2012 Jul 15;189(2):529-38. doi: 10.4049/jimmunol.1101886. Epub 2012 Jun 15.

18.

[A composite osteomusculocutaneous free flap from the medial femoral condyle: anatomic characteristics, clinical aspects, new applications].

Rahmanian-Schwarz A, Spetzler V, Willkomm LM, Eisenschenk A, Bernhard H, Schaller HE.

Handchir Mikrochir Plast Chir. 2012 Apr;44(2):67-74. doi: 10.1055/s-0032-1306360. Epub 2012 Apr 11. Review. German.

PMID:
22495956
19.

Dermal perfusion of common donor sites free flaps in chronic smokers and nonsmokers.

Rahmanian-Schwarz A, Gonser P, Willkomm L, Amr A, Held M, Schaller HE, Bernhard H.

Eplasty. 2011;11:e52. Epub 2011 Dec 19.

20.

Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.

Novak M, Schlagenhauf A, Bernhard H, Schweintzger S, Leschnik B, Muntean W.

Blood Coagul Fibrinolysis. 2011 Oct;22(7):588-92. doi: 10.1097/MBC.0b013e328349f190.

PMID:
21799400
21.

PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.

Krönig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H, Muck D, Hein R, Blank C, Peschel C, Haller B, Schulz S, Bernhard H.

Int J Cancer. 2012 May 15;130(10):2327-36. doi: 10.1002/ijc.26272. Epub 2012 Jan 11.

22.

Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells.

Thiel U, Pirson S, Müller-Spahn C, Conrad H, Busch DH, Bernhard H, Burdach S, Richter GH.

Br J Cancer. 2011 Mar 15;104(6):948-56. doi: 10.1038/bjc.2011.54. Erratum in: Br J Cancer. 2011 Aug 9;105(4):596.

23.

Microparticles in newborn cord blood: slight elevation after normal delivery.

Schweintzger S, Schlagenhauf A, Leschnik B, Rinner B, Bernhard H, Novak M, Muntean W.

Thromb Res. 2011 Jul;128(1):62-7. doi: 10.1016/j.thromres.2011.01.013. Epub 2011 Mar 4.

PMID:
21376371
24.

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

Brackertz B, Conrad H, Daniel J, Kast B, Krönig H, Busch DH, Adamski J, Peschel C, Bernhard H.

Blood Cancer J. 2011 Mar;1(3):e11. doi: 10.1038/bcj.2011.12. Epub 2011 Mar 18.

25.

Thrombin generation in pediatric patients with Crohn's disease.

Bernhard H, Deutschmann A, Leschnik B, Schweintzger S, Novak M, Hauer A, Muntean W.

Inflamm Bowel Dis. 2011 Nov;17(11):2333-9. doi: 10.1002/ibd.21631. Epub 2011 Feb 1.

PMID:
21287673
26.

Relationship between thrombin generation and carotid intima-media thickness.

Bernhard H, Wipfler P, Leschnik B, Novak M, Kraus J, Pilz G, Ladurner G, Muntean W.

Hamostaseologie. 2010 Nov;30 Suppl 1:S168-71.

PMID:
21042684
27.

High microparticle concentration in cord plasma.

Schweintzger S, Schlagenhauf A, Rinner B, Bernhard H, Novak M, Leschnik B, Muntean W.

Hamostaseologie. 2010 Nov;30 Suppl 1:S122-5.

PMID:
21042669
28.

Design of a semi-implantable hearing device for direct acoustic cochlear stimulation.

Bernhard H, Stieger C, Perriard Y.

IEEE Trans Biomed Eng. 2011 Feb;58(2):420-8. doi: 10.1109/TBME.2010.2087756. Epub 2010 Oct 18.

PMID:
20959263
29.

Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.

Meyerhuber P, Conrad H, Stärck L, Leisegang M, Busch DH, Uckert W, Bernhard H.

J Mol Med (Berl). 2010 Nov;88(11):1113-21. doi: 10.1007/s00109-010-0660-z. Epub 2010 Aug 11.

PMID:
20700725
30.

No differences in support of thrombin generation by neonatal or adult platelets.

Bernhard H, Rosenkranz A, Novak M, Leschnik B, Petritsch M, Rehak T, Köfeler H, Ulrich D, Muntean W.

Hamostaseologie. 2009 Oct;29 Suppl 1:S94-7.

PMID:
19763359
31.

Calibrated automated thrombin generation in paediatric patients with inflammatory bowel disease.

Bernhard H, Deutschmann A, Leschnik B, Novak M, Hauer A, Haidl H, Rosenkranz A, Muntean W.

Hamostaseologie. 2009 Oct;29 Suppl 1:S90-3.

PMID:
19763358
32.

Malignant stroke in an adolescent with a homozygous MTHFR 677CT mutation and intake of hormonal contraceptives.

Pfurtscheller K, Senning B, Bernhard H, Novak M, Zobel G, Plecko B, Muntean W.

Hamostaseologie. 2009 Oct;29 Suppl 1:S84-6.

PMID:
19763346
33.

Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.

Di Bonito P, Grasso F, Mochi S, Petrone L, Fanales-Belasio E, Mei A, Cesolini A, Laconi G, Conrad H, Bernhard H, Dembek CJ, Cosma A, Santini SM, Lapenta C, Donati S, Muratori C, Giorgi C, Federico M.

Virology. 2009 Dec 5;395(1):45-55. doi: 10.1016/j.virol.2009.09.012. Epub 2009 Oct 2.

34.

HLA-B*1832, a novel B allele was found through high-resolution HLA typing of a Spanish blood donor.

Witter K, Conrad H, Bernhard H, Albert T, Kauke T.

Tissue Antigens. 2009 Aug;74(2):170-2. doi: 10.1111/j.1399-0039.2009.01268.x. Epub 2009 May 20.

PMID:
19497044
35.

Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.

Krönig H, Hofer K, Conrad H, Guilaume P, Müller J, Schiemann M, Lennerz V, Cosma A, Peschel C, Busch DH, Romero P, Bernhard H.

Int J Cancer. 2009 Aug 1;125(3):649-55. doi: 10.1002/ijc.24414.

36.

Use of tumour-responsive T cells as cancer treatment.

Disis ML, Bernhard H, Jaffee EM.

Lancet. 2009 Feb 21;373(9664):673-83. doi: 10.1016/S0140-6736(09)60404-9. Review.

37.

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.

Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, Kaiser U, Aldaoud A, Jahn A; German CUP Study Group.

Br J Cancer. 2009 Jan 13;100(1):44-9. doi: 10.1038/sj.bjc.6604818. Epub 2008 Dec 9.

38.

Induction of a T helper cell response against the tumor-associated antigen HER2 using monocyte-derived dendritic cells.

Metzger J, Nicklisch N, Kufer P, Peschel C, Luppa PB, Bernhard H.

Cytotechnology. 2002 Jan;38(1-3):155-64. doi: 10.1023/A:1021103723325.

39.

Phospholipid content, expression and support of thrombin generation of neonatal platelets.

Bernhard H, Rosenkranz A, Petritsch M, Köfeler H, Rehak T, Novak M, Muntean W.

Acta Paediatr. 2009 Feb;98(2):251-5. doi: 10.1111/j.1651-2227.2008.01075.x. Epub 2008 Oct 13.

PMID:
18976372
40.

Egalitarianism in young children.

Fehr E, Bernhard H, Rockenbach B.

Nature. 2008 Aug 28;454(7208):1079-83. doi: 10.1038/nature07155.

PMID:
18756249
41.

CTLs directed against HER2 specifically cross-react with HER3 and HER4.

Conrad H, Gebhard K, Krönig H, Neudorfer J, Busch DH, Peschel C, Bernhard H.

J Immunol. 2008 Jun 15;180(12):8135-45.

42.

Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles.

Beer AJ, Holzapfel K, Neudorfer J, Piontek G, Settles M, Krönig H, Peschel C, Schlegel J, Rummeny EJ, Bernhard H.

Eur Radiol. 2008 Jun;18(6):1087-95. doi: 10.1007/s00330-008-0874-4. Epub 2008 Feb 20.

PMID:
18286290
43.

A novel implantable hearing system with direct acoustic cochlear stimulation.

Häusler R, Stieger C, Bernhard H, Kompis M.

Audiol Neurootol. 2008;13(4):247-56. doi: 10.1159/000115434. Epub 2008 Feb 7.

PMID:
18259077
44.

Human temporal bones versus mechanical model to evaluate three middle ear transducers.

Stieger C, Bernhard H, Waeckerlin D, Kompis M, Burger J, Haeusler R.

J Rehabil Res Dev. 2007;44(3):407-15.

45.

New implantable hearing device based on a micro-actuator that is directly coupled to the inner ear fluid.

Bernhard H, Stieger C, Perriard Y.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:3162-5.

PMID:
17946160
46.

Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.

Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nährig J, Fend F, Weber W, Busch DH, Peschel C.

Cancer Immunol Immunother. 2008 Feb;57(2):271-80. Epub 2007 Jul 24.

PMID:
17646988
47.

The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.

Scheich F, Duyster J, Peschel C, Bernhard H.

Blood. 2007 Oct 1;110(7):2556-60. Epub 2007 Jun 19.

PMID:
17579186
48.

Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens.

Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, Holzapfel G, Schmidt T, Germeroth L, Wagner H, Peschel C, Busch DH, Bernhard H.

J Immunol Methods. 2007 Mar 30;320(1-2):119-31. Epub 2007 Jan 31.

PMID:
17306825
49.
50.

Designer T cells by T cell receptor replacement.

Sommermeyer D, Neudorfer J, Weinhold M, Leisegang M, Engels B, Noessner E, Heemskerk MH, Charo J, Schendel DJ, Blankenstein T, Bernhard H, Uckert W.

Eur J Immunol. 2006 Nov;36(11):3052-9.

Supplemental Content

Loading ...
Support Center